Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML
NCT07091006
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
44
Enrollment
OTHER
Sponsor class
Conditions
Relapse Leukemia
Interventions
DRUG:
VAH
Sponsor
Ruijin Hospital